More is not better: PARP dose can be safely reduced for people with ovarian cancer
Full article: https://www.annalsofoncology.org/article/S0923-7534(22)00338-6/fulltext
Maintenance therapy with a PARP inhibitor is now the standard of care for many people with advanced or recurrent ovarian cancer. However, PARP inhibitors may have significant side effects. This study shows that reducing the dose of a PARP inhibitor does not affect survival. (Posted 11/8/22)
Este artículo está disponible en español.
The following NCCN recommendations are for maintenance therapy for women with ovarian cancer who have had a complete or partial response to first-line therapy:
- Women who have a BRCA mutation may benefit from a PARP inhibitor as maintenance therapy.
- Women who have a BRCA mutation and had Avastin as part of their first-line treatment may benefit from a PARP inhibitor alone or Lynparza and Avastin as maintenance therapy.
- Women who do not have a BRCA mutation and had Avastin as part of their first-line treatment may benefit from a PARP inhibitor alone or in combination with Avastin as maintenance therapy, depending on the homologous recombination deficiency (HRD) status of their cancer.
- Women who do not have a BRCA mutation and did not have Avastin as part of their first-line treatment may benefit from a PARP inhibitor as maintenance therapy.
Questions To Ask Your Health Care Provider
- Is olaparib maintenance therapy an option for me?
- What side effects of olaparib therapy could lead to the need to reduce the dose or interrupt treatment?
- How will the side effects of olaparib therapy be monitored and managed?
- How will I know whether I should take my daily olaparib dose or not?
Open Clinical Trials
The following are studies looking at PARP inhibitors and similar agents for treating people with ovarian cancer.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.